Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
epilepsy
NeuroOne CEO Joins Today’s Marketplace To Discuss The Latest Treatments for Epilepsy
18 mars 2025 08h46 HE
|
Today's Marketplace
Today's Marketplace interview about epilepsy treatment with NeuroOne CEO and Creighton University
Montara Therapeutics Closes $20M Oversubscribed Seed Expansion, Appoints Troy Wilson as Chairman of the Board
13 mars 2025 08h00 HE
|
Montara Therapeutics
Montara Therapeutics closed a $20 million oversubscribed expansion of its Series Seed financing. Troy Wilson joins as Chairman of the Board.
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
11 mars 2025 08h33 HE
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Kaerus Bioscience Successfully Completes Phase 1 Trial and Demonstrates Proof of Mechanism with its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
11 mars 2025 06h00 HE
|
Kaerus Bioscience
Kaerus announces its novel BK channel modulator KER-0193 is safe and well tolerated in Phase 1, also demonstrating proof of mechanism with EEG biomarker.
Catalyst Pharmaceuticals to Participate in the Barclays 27th Annual Global Healthcare Conference
04 mars 2025 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., March 04, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
26 févr. 2025 16h13 HE
|
Catalyst Pharmaceuticals, Inc.
Full Year 2024 Total Revenues of $491.7 Million, Marking Another Year of Record Growth Full Year 2024 Total Revenues Grew 23.5% YoY, Driven by Strong Commercial Performance ...
[Latest] Global Neurostimulation Device Market Size/Share Worth USD 22,299.61 Million by 2034 at a 11.98% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
26 févr. 2025 11h30 HE
|
Custom Market Insights
Austin, TX, USA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Neurostimulation Device Market Size, Trends and Insights By Product (Spinal Cord...
Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight
20 févr. 2025 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight According to...
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
20 févr. 2025 12h00 HE
|
Neurona Therapeutics
Neurona Unveils Phase 3 EPIC Study for NRTX-1001 Cell Therapy in Epilepsy
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2024 Financial Results on February 26, 2025
12 févr. 2025 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...